Experience with Epifast® cryopreserved epidermal allograft in the treatment of superficial and deep second-degree burns: Retrospective study of 297 cases, 2010–2015
Pablo Rodriguez-Ferreyra,
Omar Gayosso-Cerón,
Rosalba Alonso-Campero,
Adriana Tellez-Tellez,
Ramiro Balderas-Sánchez,
Martin Funk,
Alma P. Reyes-Ibarra
Affiliations
Pablo Rodriguez-Ferreyra
Hospital General “Dr. Nicolás San Juan”, ISEM, Privada Nicolás San Juan s/n, Ex-hacienda La Magdalena, Toluca de Lerdo, Estado de México 50010, Mexico; Corresponding author at: Hospital General Nicolás San Juan, Privada Nicolás San Juan s/n, Ex-hacienda La Magdalena, Toluca, C.P. 50010 Toluca de Lerdo, Estado de México, Mexico.
Omar Gayosso-Cerón
Hospital General “Dr. Nicolás San Juan”, ISEM, Privada Nicolás San Juan s/n, Ex-hacienda La Magdalena, Toluca de Lerdo, Estado de México 50010, Mexico
Rosalba Alonso-Campero
Asociación Mexicana para la Investigación Clínica, A.C., Cumbres 107, Colonia Hacienda, Pachuca, Hidalgo 42070, Mexico
Adriana Tellez-Tellez
Asociación Mexicana para la Investigación Clínica, A.C., Cumbres 107, Colonia Hacienda, Pachuca, Hidalgo 42070, Mexico
Ramiro Balderas-Sánchez
Asociación Mexicana para la Investigación Clínica, A.C., Cumbres 107, Colonia Hacienda, Pachuca, Hidalgo 42070, Mexico
The objective of this study was to describe our experience with Epifast cryopreserved epidermal allograft (CEA) in children with second degree burns. We examined the number of days required for epithelialization, after the use of the Epifast® cryopreserved epidermal allograft (CEA). We examined medical records of 297 patients with superficial and deep second-degree burns treated with Epifast® CEA between January 2010 and December 2015 in the Pediatric Burn Unit of Nicolás San Juan Hospital, Toluca, Mexico. We included pediatric patients from newborn to 17 years of age, with burned body surface areas ≤30%, who were treated with tangential escharotomy and Epifast® CEA at the instructions of the treating physicians. Epithelialization occurred in an average of 7.5 days (SD = 7.4 days) after the initial application of Epifast® CEA. The most frequent epithelialization time was 5 days (24.2%), followed by 6–7 days (12.8%) and 4 days (10.8%). None of the 297 medical records contained a report of an adverse effect related to Epifast® CEA use. Keywords: In vitro culture, Keratinocyte, Second-degree burn, Epidermal allograft
